COMPLETEDN/A

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

The purpose of the study is to test and understand acceptability and preliminary effectiveness of a mobile educational app specifically customized to patients with advanced Renal Cell Carcinoma (RCC) receiving therapy with combination immunotherapy.

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Enrollment

20 participants

Sites

1 locations

Start Date

October 2022

Completion

January 2024

Renal Cell Carcinoma Stage IVmHealth Smart Phone ApplicationeHEALS digital literacy testWeekly Quiz

Enrollment & Timeline

Completed

Target N

participants

Sites

locations

Duration

2.1 years

total trial span

Rate

pts/month needed

At 1 sites, each site needs to enroll approximately 1.0 patients/month to hit the enrollment target on schedule.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

Acceptability of Smart Phone Application

at 6 months

Patient's acceptability of the smart phone application for education will be captured in the patient post education survey.

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors.

Roman Souza Gabriel, Turner Kea, Gullapalli Keerthi et al.JCO clinical cancer informatics2024

DOI PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Fetching protocol from ClinicalTrials.gov…

COMPLETEDN/A

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Enrollment

20 participants

Sites

1 locations

Start Date

October 2022

Completion

January 2024

Renal Cell Carcinoma Stage IVmHealth Smart Phone ApplicationeHEALS digital literacy testWeekly Quiz

Enrollment & Timeline

Completed

Target N

participants

Sites

locations

Duration

2.1 years

total trial span

Rate

pts/month needed

At 1 sites, each site needs to enroll approximately 1.0 patients/month to hit the enrollment target on schedule.

View on ClinicalTrials.gov

Ask AI

Primary Outcomes

Acceptability of Smart Phone Application

at 6 months

Patient's acceptability of the smart phone application for education will be captured in the patient post education survey.

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors.

Roman Souza Gabriel, Turner Kea, Gullapalli Keerthi et al.JCO clinical cancer informatics2024

DOI PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Eligibility

Min Age

18 Years

Sex

all

Healthy Volunteers

View full criteria

Inclusion Criteria:

* Patients with Stage IV Renal Cell Carcinoma
* Within 3 weeks from starting combination immune checkpoint blockade with tyrosine kinase inhibitor or multikinase inhibitor
* Estimated survival of 6 months or more
* Able to read and speak English

Exclusion Criteria:

* Unable to read or speak English
* Enrolled in another clinical trial

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy

Enrollment & Timeline

Primary Outcomes

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Eligibility

Trial Sites (1)